Heterocyclic acetamide compounds of the present invention have a dopamine D1 receptor positive allosteric modulating activity and can be used as an agent for preventing and/or treating cognitive impairment, negative symptoms of schizophrenia, Parkinson's disease, Alzheimer's disease, Huntington's disease, drug addictions, or the like.
HETEROCYCLIC ACETAMIDE COMPOUNDS AS DOPAMINE D1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS (D1 PAM)